Bloomberg News

Baxter Wins Conditional Approval From EU to Buy Gambro

July 22, 2013

Baxter International Inc. (BAX:US), the world’s second-largest maker of dialysis products, won conditional approval from European Union to buy Swedish competitor Gambro AB to expand its kidney-equipment business.

To allay competition issues, Baxter agreed to divest its continuous renal replacement therapy (CRRT) business, which serves patients suffering from acute kidney failure, the European Commission said in an e-mailed statement today.

To contact the reporter on this story: Gaspard Sebag in Brussels at gsebag@bloomberg.net

To contact the editor responsible for this story: Peter Chapman at pchapman10@bloomberg.net


Toyota's Hydrogen Man
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • BAX
    (Baxter International Inc)
    • $74.48 USD
    • 0.41
    • 0.55%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus